In this review, we will focus on the recent progress on mesenchymal stem cells (MSCs) derived cardiomyocytes for cardiac regeneration after myocardial infarction (MI).
Our review aims to provide an updated account of microbiological characteristics, clinical presentation, diagnosis, and management of Mycobacterium chimaera infections, with a special focus on those developing after cardiothoracic surgery.